Cargando…

Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis

INTRODUCTION: Sarcoidosis is a multisystem, inflammatory, systemic granulomatous disease with unknown etiology. Despite the current standard of care (SoC), there is an unmet need for the treatment of advanced symptomatic sarcoidosis. This study assessed the cost-effectiveness of Acthar(®) Gel (repos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bindra, Jas, Chopra, Ishveen, Hayes, Kyle, Niewoehner, John, Panaccio, Mary, Wan, George J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590138/ https://www.ncbi.nlm.nih.gov/pubmed/37868649 http://dx.doi.org/10.2147/CEOR.S428466

Ejemplares similares

Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus
por: Bindra, Jas, et al.
Publicado: (2022)

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)

Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis
por: Hayes, Kyle, et al.
Publicado: (2023)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence
por: Wan, George J, et al.
Publicado: (2023)

Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
por: Huang, Xingyue, et al.
Publicado: (2023)

Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
por: Zhou, Ying, et al.
Publicado: (2015)

Acthar Gel Inhibits the Activation of CD4(+) and CD8(+) T Cells
por: Wright, Dale, et al.
Publicado: (2023)

Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis
por: Wan, George J, et al.
Publicado: (2020)

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records
por: Chopra, Ishveen, et al.
Publicado: (2019)

A Narrative Review of Acthar Gel for the Treatment of Myositis
por: Chandra, Tanya, et al.
Publicado: (2023)

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(®) Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

A Systematic Literature Review and Indirect Treatment Comparison of Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms
por: Duchowny, Michael S., et al.
Publicado: (2021)

Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
por: Girman, Cynthia, et al.
Publicado: (2022)

Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series
por: Madan, Arvind, et al.
Publicado: (2016)

Direct effects of HP Acthar Gel(®) on human B lymphocyte activation in vitro
por: Olsen, Nancy J., et al.
Publicado: (2015)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Acthar(®) Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence
por: Kaplan, Jeffrey, et al.
Publicado: (2023)

Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection
por: Hayes, Kyle, et al.
Publicado: (2021)

Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy
por: Tumlin, James, et al.
Publicado: (2017)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Membranous glomerulopathy and treatment with Acthar®: a case study
por: Watson, Myra June
Publicado: (2013)

Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases
por: Markell, Mariana, et al.
Publicado: (2019)

ACTH (Acthar Gel) Reduces Toxic SOD1 Protein Linked to Amyotrophic Lateral Sclerosis in Transgenic Mice: A Novel Observation
por: Arrat, Hasan, et al.
Publicado: (2015)

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy
por: Hladunewich, Michelle A., et al.
Publicado: (2014)

Repository Corticotropin Injection (Acthar(®) Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study
por: Wirta, David, et al.
Publicado: (2021)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

Spontaneous Resolution of Symptomatic Hepatic Sarcoidosis
por: Nguyen, Viva, et al.
Publicado: (2018)

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
por: Askanase, Anca D, et al.
Publicado: (2020)

A symptomatic gastric sarcoidosis and asymptomatic pulmonary sarcoidosis: a rare manifestation
por: Bhattarai, Bikash, et al.
Publicado: (2019)

Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis
por: Hayes, Kyle, et al.
Publicado: (2021)

Follow-up care for breast cancer survivors: improving patient outcomes
por: Chopra, Ishveen, et al.
Publicado: (2014)

P03-013 - Symptomatic neuromuscular sarcoidosis
por: Mulazzani, M, et al.
Publicado: (2013)

Corrigendum to “Spontaneous Resolution of Symptomatic Hepatic Sarcoidosis”
por: Nguyen, Viva, et al.
Publicado: (2018)

Severe Symptomatic Anemia in Gastrointestinal Tract Sarcoidosis
por: Tao, Jin, et al.
Publicado: (2023)

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
por: Rice, J. Bradford, et al.
Publicado: (2020)

COVID-19 INFECTION AS A CAUSE FOR PROGRESSION OF PREVIOUSLY ASYMPTOMATIC SARCOIDOSIS TO SYMPTOMATIC SARCOIDOSIS
por: HARTMANN, SKYLAR, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bjhqc8qaqkmo7fs2sret63pncc